Rett Syndrome Therapeutics Review, H2 2018 - Pipeline Analysis of 16 Companies & Drug Profiles - ResearchAndMarkets.com
The "Rett Syndrome - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Rett Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Rett Syndrome - Overview
- Rett Syndrome - Therapeutics Development
- Rett Syndrome - Therapeutics Assessment
- Rett Syndrome - Companies Involved in Therapeutics Development
- Rett Syndrome - Drug Profiles
- Rett Syndrome - Dormant Projects
- Rett Syndrome - Product Development Milestones
- AMO Pharma Ltd
- Amorsa Therapeutics Inc
- Anavex Life Sciences Corp
- ArmaGen Inc
- AveXis Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Eloxx Pharmaceuticals Inc
- GW Pharmaceuticals Plc
- Mitochon Pharmaceuticals Inc
- Mitsubishi Tanabe Pharma Corp
- Neuren Pharmaceuticals Ltd
- Neurolixis Inc
- Newron Pharmaceuticals SpA
- OPKO Health Inc
- Relmada Therapeutics Inc
- Ultragenyx Pharmaceutical Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ctv2j8/rett_syndrome?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005617/en/